Cannabinoid Receptor Agonists
"Cannabinoid Receptor Agonists" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Compounds that interact with and stimulate the activity of CANNABINOID RECEPTORS.
| Descriptor ID |
D063386
|
| MeSH Number(s) |
D27.505.519.625.085.500 D27.505.696.399.472.188.500
|
| Concept/Terms |
Cannabinoid Receptor Agonists- Cannabinoid Receptor Agonists
- Agonists, Cannabinoid Receptor
- Receptor Agonists, Cannabinoid
- Cannabinoid Receptor Activators
- Activators, Cannabinoid Receptor
- Receptor Activators, Cannabinoid
- Cannabinoid Agonists
- Agonists, Cannabinoid
|
Below are MeSH descriptors whose meaning is more general than "Cannabinoid Receptor Agonists".
Below are MeSH descriptors whose meaning is more specific than "Cannabinoid Receptor Agonists".
This graph shows the total number of publications written about "Cannabinoid Receptor Agonists" by people in this website by year, and whether "Cannabinoid Receptor Agonists" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2017 | 0 | 2 | 2 |
| 2018 | 4 | 1 | 5 |
To return to the timeline, click here.
Below are the most recent publications written about "Cannabinoid Receptor Agonists" by people in Profiles.
-
Increase in drugs-of-abuse findings in post-mortem toxicology due to COVID-19 restrictions-First observations in Finland. Drug Test Anal. 2021 Apr; 13(4):867-870.
-
CB2 receptor-selective agonists as candidates for targeting infection, inflammation, and immunity in SARS-CoV-2 infections. Drug Dev Res. 2021 02; 82(1):7-11.
-
?9-Tetrahydrocannabinol Prevents Mortality from Acute Respiratory Distress Syndrome through the Induction of Apoptosis in Immune Cells, Leading to Cytokine Storm Suppression. Int J Mol Sci. 2020 Aug 28; 21(17).
-
A Systematic Review of the Efficacy of Cannabinoid Agonist Replacement Therapy for Cannabis Withdrawal Symptoms. CNS Drugs. 2018 12; 32(12):1113-1129.
-
Case of brodifacoum-contaminated synthetic cannabinoid. Clin Toxicol (Phila). 2019 02; 57(2):143-144.
-
Anandamide and endocannabinoid system: an attractive therapeutic approach for cardiovascular disease. Ther Adv Cardiovasc Dis. 2018 Jul; 12(7):177-190.
-
In Vitro Inhibitory Effects of Synthetic Cannabinoid EAM-2201 on Cytochrome P450 and UDP-Glucuronosyltransferase Enzyme Activities in Human Liver Microsomes. Molecules. 2018 04 16; 23(4).
-
Insights into future therapeutics for atopic dermatitis. Expert Opin Pharmacother. 2018 02; 19(3):265-278.
-
Bladder cancer cell growth and motility implicate cannabinoid 2 receptor-mediated modifications of sphingolipids metabolism. Sci Rep. 2017 02 13; 7:42157.
-
Clinical Evidence for Utilizing Cannabinoids in the Elderly. Isr Med Assoc J. 2017 Feb; 19(2):71-75.